Skip to main content
OpenTrials
Completed

NCT Number: NCT03653897

Performance of the ID-Cap System, an Ingestion Event Marker, in the Clinical Setting as an Aid to Measure Medication Adherence

The ID-Cap System is classified as an ingestion event marker (IEM), a Class II medical device. The system is intended to record time-stamped ingestions with the ingestible sensor, ID-Tag which transmits a signal to a wearable device, the ID-Cap Reader. In this study, 12-18 subjects will ingest capsules containing ingestible sensors while wearing the Reader and being observed in a clinic setting.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers Behavior Health Behavior Medication Adherence Patient Acceptance of Health Care Patient Compliance Treatment Adherence and Compliance

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Quotient Sciences

Miami, Florida, 33126, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Enrollment will be stratified to include at least two study participants in each BMI-Gender category. The BMI-Gender categories will be: Normal/Underweight (BMI<25), Overweight (BMI 25.0 to <30), and Obese (BMI>30.0); and Male/Female.

Inclusion criteria

  • Men and women 18 years of age or older.
  • For females of childbearing potential, negative urine pregnancy test at time of entry and assurance that a medically-accepted means of contraception will be used for the duration of the study.
  • Able and willing to provide informed consent.
  • Willing to adhere to all protocol requirements and study procedures.
  • Adequate organ function at screening.

Exclusion criteria

  • Unable to take oral medications.
  • Women who are pregnant, breast-feeding, or plan to become pregnant during the study, and females of childbearing potential who are not using a medically-accepted means of contraception.
  • Medical condition which may affect passage through the gastrointestinal tract (including, but not limited to, small bowel tumors, symptomatic intestinal adhesions, symptomatic active ulcerations, and radiation enteritis).
  • Known hypersensitivity to any component of the ingestible ID-Capsule (including, but not limited to, gelatin, polyimide, magnesium, or silver).
  • Significant medical condition, psychiatric condition, current alcohol or drug abuse, or other condition which may preclude the study participant from being able to follow study procedures or to safely participate in the opinion of the investigator.
  • Participation in an investigational product study (e.g., medical device or drug study) within 30 days prior to screening, or prior participation in an Ingestion Event Marker study.
  • Presence of an active implantable electronic medical device.
  • Positive screen for drugs of abuse (detection of drug for which a valid prescription exists is not exclusionary).
  • Any laboratory test result deemed clinical significant by the Investigator.

Treatment and study plan

ID-Capsule- Active

Device

A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.

wearable sensor

Device

Subjects will wear an ID-Reader

Primary outcomes

  1. Positive Detection Accuracy (PDA)

    Time frame: Up to 6 days

    The number of active ingestible sensors detected divided by the number of active ingestible sensors administered under direct observation.

  2. Negative Detection Accuracy (NDA)

    Time frame: Up to 6 days

    The number of inactive empty capsules not detected divided by the number of inactive empty capsules administered under direct observation. Determination of NDA will also include the number of monitoring periods with no ingestion events detected by the Reader divided by the number of specific monitoring periods performed for the purpose of detecting false positives.

Secondary outcomes

  1. Number of Study Participants with Adverse Events as a Measure of Safety and Tolerability

    Time frame: Up to 6 days during ingestion events through the follow-up assessment scheduled within 3 to 5 days of the last ingestion]

    Incidence of mild, moderate, and severe adverse events overall and related to the device; discontinuations due to adverse events

Other outcomes

  1. Detection Time

    Time frame: Up to 60 minutes post ingestion

    Time from ingestion of ID-Capsule to first detection by the ID-Cap Reader

  2. Signal Duration

    Time frame: Up to 60 minutes post ingestion

    Time from first to last detection of the signal from the ingested sensor by the ID-Cap Reader

Sponsors and collaborators

Lead sponsor

EtectRX, Inc.

Industry

Collaborators

  • Quotient Sciences

Registry information

Official study title

Performance of the ID-Cap System, in the Clinical Setting as an Aid to Measure Medication Adherence (DO Trial 2.0)

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Aug 31, 2018
Registry last updated
Aug 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.